Ovarian cancer drug ‘most significant’ PBS listing in 30 years

Google+ Pinterest LinkedIn Tumblr +

woman taking medicationSBS

The quality of life for hundreds of women with advanced ovarian cancer is set to improve with an effective new drug treatment listed on the PBS.

A drug that provides quality of life for women who have an inherited form of advanced ovarian cancer has been listed on the Pharmaceutical Benefits Scheme, offering a ray of hope in the battle against the deadly disease.

The PBS listing of Lynparza (olaparib), the first oral prescription medicine for women with BRCA-mutated advanced ovarian cancer, has been heralded as the “most significant development in the past 30 years” in treatment…read the full story and watch the report here.

Share.

About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Comments are closed.